Markets:

Overview

News

Currencies

International

Treasuries

Kymera Therapeutics, Inc. - Common Stock (NQ:KYMR)

66.25 +0.02 (+0.02%)

Streaming Delayed Price Updated: 1:41 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Kymera Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Why Kymera Therapeutics Stock Is Gaining Wednesday ↗

June 01, 2022

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Kymera Therapeutics (NASDAQ: KYMR) lead drug candidate KT-333 for the treatment of patients with Peripheral T-cell...

Via Benzinga

Analyst Ratings for Kymera Therapeutics ↗

June 01, 2022

Kymera Therapeutics (NASDAQ:KYMR) has observed the following analyst ratings within the last quarter:

Via Benzinga

Fresh Del Monte Produce And 2 Other Stocks Insiders Are Buying ↗

June 01, 2022

Although the Dow Jones dropped more than 200 points on Tuesday, there were a few notable insider trades.

Via Benzinga

3 Biotech Stocks to Buy Before They Boom ↗

June 01, 2022

It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations.

Via InvestorPlace

Executives Buy Around $141M Of 4 Stocks ↗

May 10, 2022

Although Dow Jones futures traded higher this morning on Tuesday, there were a few notable insider trades.

Via Benzinga

Mid-Afternoon Market Update: Kymera Therapeutics Drops After Q1 Results; Belite Bio Shares Spike Higher ↗

May 03, 2022

U.S. stocks traded slightly higher toward the end of trading on Tuesday.

Via Benzinga

Why Kymera Therapeutics Shares Are Falling Today ↗

May 03, 2022

Via Benzinga

Kymera Therapeutics: Q1 Earnings Insights ↗

May 03, 2022

Kymera Therapeutics (NASDAQ:KYMR) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

81 Biggest Movers From Yesterday ↗

May 05, 2022

Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares climbed 62.4% to close at $2.16 on Wednesday after gaining around 5% on Tuesday.

Via Benzinga

Analyst Ratings for Kymera Therapeutics ↗

April 28, 2022

Kymera Therapeutics (NASDAQ:KYMR) has observed the following analyst ratings within the last quarter:

Via Benzinga

50 Stocks Moving In Wednesday's Mid-Day Session ↗

May 04, 2022

Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares jumped 51.7% to $2.0180 after gaining around 5% on Tuesday. Sharps Technology, Inc. (NASDAQ: STSS) rose 31.4% to $1.6815 after...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

May 03, 2022

Via Benzinga

80 Biggest Movers From Yesterday ↗

May 04, 2022

Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 93.1% to close at $6.45 on Tuesday on above-average volume. XORTX Therapeutics Inc. (NASDAQ: XRTX) gained 59.1% to...

Via Benzinga

Mid-Day Market Update: Dow Jumps 100 Points; Spero Therapeutics Shares Plunge ↗

May 03, 2022

U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 100 points on Tuesday.

Via Benzinga

41 Stocks Moving In Tuesday's Mid-Day Session ↗

May 03, 2022

Gainers SoundHound AI, Inc. (NASDAQ: SOUN) shares jumped 47.4% to $16.13. The company recently completed a SPAC merger deal last week and began trading on Thursday. Sonoma...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022 ↗

April 28, 2022

Via Benzinga

Kymera Therapeutics Q1 2022 Earnings Conference Call On May 3, 2022 At 08:00 AM ET ↗

April 21, 2022

Kymera Therapeutics (NASDAQ:KYMR) will host a conference call at 08:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results. How to Attend Kymera Therapeutics (KYMR) Conference Call Follow this...

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

March 18, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

JPMorgan Sees 'Limited Upside Potential' In Kymera Therapeutics' KT-474 ↗

March 10, 2022

JPMorgan has initiated the coverage of Kymera Therapeutics Inc (NASDAQ: KYMR) with a Neutral rating and a $44 price target. Analyst Eric Joseph says...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2022 ↗

March 10, 2022

Upgrades For Alpha Metallurgical Resources Inc (NYSE:AMR), B. Riley Securities upgraded the previous rating of Neutral to Buy. For the fourth quarter, Alpha Metallurgical...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2022 ↗

February 10, 2022

Upgrades According to Gordon Haskett, the prior rating for Williams-Sonoma Inc (NYSE:WSM) was changed from Hold to Accumulate. Williams-Sonoma earned $3.32 in the third quarter,...

Via Benzinga

48 Biggest Movers From Yesterday ↗

January 14, 2022

Gainers Singularity Future Technology Ltd. (NASDAQ: SGLY) shares rose 25.9% to settle at $5.01 on Thursday. MedAvail Holdings, Inc (NASDAQ: MDVL) gained 24.4% to settle at $1.58...

Via Benzinga

Kymera Discloses New Development Cancer Program ↗

December 16, 2021

Kymera Therapeutics Inc (NASDAQ: KYMR) has added KT-253 to its pipeline, targeted at liquid and solid tumors. KT-253, a selective degrader of MDM2, has the potential to...

Via Benzinga

The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street ↗

December 16, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug...

Via Benzinga

Where Kymera Therapeutics Stands With Analysts ↗

September 30, 2021

Over the past 3 months, 5 analysts have published their opinion on Kymera Therapeutics (NASDAQ:

Via Benzinga

The Past Week's Notable Insider Buys Include Krispy Kreme, Biotechs, SPACs And More ↗

July 11, 2021

Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Initial and secondary public offerings enticed insiders to...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021 ↗

September 30, 2021

Upgrades For Cabot Oil & Gas Corp (NYSE:COG),...

Via Benzinga

Kymera Prices $223M Equity Offering At $47/Share ↗

July 01, 2021

Kymera Therapeutics Inc (NASDAQ: KYMR) has priced its upsized underwritten public offering of 4.7 million shares at $47.00 per share, representing a discount...

Via Benzinga

The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold ↗

September 17, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Bicycle Therapeutics plc (...

Via Benzinga

58 Biggest Movers From Yesterday ↗

July 02, 2021

Gainers The Glimpse Group, Inc. (NASDAQ: VRAR) shares jumped 152.3% to settle at $17.66 on Thursday after the company priced its IPO at $7 per share. Pop Culture Group Co., Ltd (...

Via Benzinga

Topics Initial Public Offering

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Kymera Therapeutics, Inc. - Common Stock (NQ:KYMR)

All News about Kymera Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today